The C-terminal HSP90 inhibitor NCT-58 kills trastuzumab-resistant breast cancer stem-like cells

Cancers, Free Full-Text

Following the design path of isoform-selective Hsp90 inhibitors: Small differences, great opportunities - ScienceDirect

PDF) A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response

β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features, Cancer Cell International

Following the design path of isoform-selective Hsp90 inhibitors: Small differences, great opportunities - ScienceDirect

Biomolecules, Free Full-Text

An ErbB-2 molecule unable to bind Hsp90 shows enhanced activity. (A)

NCT-58, HSP90 C-terminal Inhibitor

β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features, Cancer Cell International

PDF) A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response

Recent advances toward the development of Hsp90 C-terminal inhibitors - ScienceDirect

β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features, Cancer Cell International

PDF) A novel HSP90 inhibitor targeting the C-terminal domain attenuates trastuzumab resistance in HER2-positive breast cancer

Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer

Cancers, Free Full-Text